Marginum and Mediplast has initiated a strategic collaboration.
The partnership aims to strengthen the availability and accessibility of Marginum’s products in the Nordics.
Mediplast will serve as the distributor of Marginum’s novel HIVEN® aspirate tissue monitoring technology in Nordic countries (Norway, Sweden, Denmark, and Finland). With a strong commitment to clinical excellence and innovation, Mediplast collaborates closely with healthcare providers to ensure that its products meet the highest standards of safety, functionality and performance.
“We are excited to join forces with Mediplast”, says Samu Lehtonen MD, CEO of Marginum. “Their extensive network, deep market knowledge and proven track record in medical device distribution make them an ideal partner as we expand our global footprint in delivering innovative solutions to healthcare providers and patients.”
The collaboration reflects a shared commitment to improving patient outcomes and surgical cost-effectiveness through novel medical technology and streamlined delivery channels. By leveraging Mediplast’s logistics infrastructure and strong customer relationships, Marginum aims to accelerate the adoption of the aspirate tissue monitoring surgical technique and the HIVEN® device by providing timely support to healthcare professionals.
“Partnering with Marginum aligns perfectly with our mission to bring the highest quality medical products to those who need them the most”, says Hans Wallén, Sales & Marketing Director of Mediplast. “We look forward to a successful collaboration that will benefit our customers and ultimately improve lives.”
The partnership will take effect immediately following EU MDR certification for HIVEN®.
Figure 1. Live demonstration of HIVEN® device at Mediplast Malmö office held by Marginum’s Chief Medical Officer Sami Puustinen.
